Skandinaviska Enskilda Banken (SEB)’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-16,500
| Closed | -$910K | – | 796 |
|
|
2023
Q4 | $910K | Buy |
16,500
+4,700
| +40% | +$259K | 0.01% | 707 |
|
|
2023
Q3 | $685K | Buy |
+11,800
| New | +$685K | ﹤0.01% | 731 |
|
|
2020
Q4 | – | Sell |
-4,800
| Closed | -$135K | – | 1129 |
|
|
2020
Q3 | $135K | Buy |
+4,800
| New | +$135K | ﹤0.01% | 925 |
|
|
2019
Q3 | – | Sell |
-28,600
| Closed | -$2.35M | – | 916 |
|
|
2019
Q2 | $2.35M | Sell |
28,600
-15,500
| -35% | -$1.27M | 0.02% | 464 |
|
|
2019
Q1 | $3.11M | Sell |
44,100
-2,600
| -6% | -$183K | 0.03% | 366 |
|
|
2018
Q4 | $2.1M | Buy |
46,700
+6,200
| +15% | +$279K | 0.02% | 463 |
|
|
2018
Q3 | $2.29M | Buy |
40,500
+6,700
| +20% | +$379K | 0.02% | 447 |
|
|
2018
Q2 | $2.26M | Sell |
33,800
-5,300
| -14% | -$354K | 0.02% | 405 |
|
|
2018
Q1 | $2.28M | Buy |
39,100
+1,500
| +4% | +$87.3K | 0.02% | 375 |
|
|
2017
Q4 | $2.42M | Sell |
37,600
-17,300
| -32% | -$1.11M | 0.02% | 400 |
|
|
2017
Q3 | $2.88M | Buy |
54,900
+25,300
| +85% | +$1.33M | 0.03% | 389 |
|
|
2017
Q2 | $1.39M | Buy |
29,600
+24,800
| +517% | +$1.16M | 0.01% | 548 |
|
|
2017
Q1 | $238K | Buy |
+4,800
| New | +$238K | ﹤0.01% | 719 |
|
|
2016
Q3 | – | Sell |
-47,500
| Closed | -$2.65M | – | 708 |
|
|
2016
Q2 | $2.65M | Sell |
47,500
-81,500
| -63% | -$4.55M | 0.03% | 385 |
|
|
2016
Q1 | $4.34M | Sell |
129,000
-13,900
| -10% | -$468K | 0.05% | 266 |
|
|
2015
Q4 | $6.7M | Buy |
+142,900
| New | +$6.7M | 0.09% | 178 |
|